HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Claims May Present Challenges For Marketers – Nestle Rep

This article was originally published in The Tan Sheet

Executive Summary

Although qualified health claims are a step in the right direction for FDA and industry, they may not help nutritional manufacturers sell their products, according to a Nestle executive

You may also be interested in...

Green Tea Cancer Prevention Claims Offered By FDA Stress Data Limits

FDA emphasizes the negative in its specified wording for qualified health claims that may link green tea with prevention of breast and prostate cancers

FDA Health Claims Initiative On Crawford’s Priority List

FDA's revised approach to regulating health claims for dietary supplements and foods has an advocate in acting commissioner-designate Lester Crawford, PhD

Highly Qualified Health Claims May Not Appeal To Consumers – FTC

Preliminary results from Federal Trade Commission research suggests there may be little incentive for marketers to incur costs to make highly qualified health claims for dietary supplements, the commission suggests in Jan. 26 comments to FDA

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts